Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-06-27
2011-10-11
Audet, Maury (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021800, C514S019200, C514S019500, C514S019600, C514S019800, C530S329000, C424S001690
Reexamination Certificate
active
08034781
ABSTRACT:
The present invention describes the use of angiotensin-(1-7) peptide as an anti-cancer therapeutic. Thus, in one embodiment, the present invention comprises a composition to inhibit the growth of cancer cells in an individual comprising a pharmaceutically effective amount of an agonist for the angiotensin-(1-7) receptor to inhibit cancer cell growth or proliferation. Application of a pharmaceutically effective amount of angiotensin-(1-7) or angiotensin-(1-7) receptor agonist is associated with an increase in the expression of genes involved in tumor suppression, apoptosis, and/or cell cycle inhibition, and a decrease the expression of known oncogenes, protein kinases, and/or cell cycle progression genes. Cancers treated using the methods and compositions described herein include cancers having an angiotensin-(1-7) receptor, including, but not limited to, breast and lung cancer.
REFERENCES:
patent: 5015629 (1991-05-01), diZerega
patent: 5567677 (1996-10-01), Castensson et al.
patent: 6235766 (2001-05-01), Heitsch et al.
patent: 6239109 (2001-05-01), Rodgers et al.
patent: 6258778 (2001-07-01), Rodgers et al.
patent: 6267958 (2001-07-01), Andya et al.
patent: 6429222 (2002-08-01), Heitsch et al.
patent: 6455500 (2002-09-01), Rodgers et al.
patent: 6475988 (2002-11-01), Rodgers et al.
patent: 6566335 (2003-05-01), Rodgers et al.
patent: 7122523 (2006-10-01), Rodgers et al.
patent: 7375073 (2008-05-01), Tallant et al.
patent: 7375075 (2008-05-01), Basler et al.
patent: 2002/0165141 (2002-11-01), diZerega et al.
patent: 2004/0176302 (2004-09-01), Rodgers et al.
patent: WO 98/32423 (1998-07-01), None
patent: WO 99/40106 (1999-08-01), None
patent: WO 02/087504 (2002-11-01), None
patent: WO 03/039434 (2003-05-01), None
Tallant et al. Ang-(1-7) Inhibits Growth of Malignant Cells. Slide Presentation. Dec. 1999. Submitted as part of Apr. 14, 2009 Declaration.
Tallant et al. Ang-(1-7) Inhibits Growth of Malignant Cells. Slide Presentation. Dec. 1999. (with Apr. 13, 2009 Affidavit, Exhibit A).
“Inhibition of Human Lung Cancer Cell Growth by Angiotensin-(I-7),” Abstract #2181 in the Proceedings of the American Association for Cancer Research, vol. 42, p. 405, Mar. 2001 (with Apr. 13, 2009 Affidavit, Exhibit B).
“Attenuation of Human Breast and Lung Cancer Cell Growth by Angiotensin-(I-7),” FASEB Journal, vol. 15(4), Mar. 2001, as Abstract 637.7 (with Apr. 13, 2009 Affidavit as Exhibit C).
Bailar et al. (New England Journal of Medicine, 1997, vol. 336, No. 22, pp. 1569-1574) (available Online @ Pub Med).
Ambuhl et al., “Effects of angiotensin analogues and angiotensin receptor antagonists on paraventricular neurons,”Regul. Pept., 1992, 38:111-120.
Appel, “Mechanisms of atrial natriuretic factor-induced inhibition of rat mesangial cell mitogenesis,”Am.J.Physiol, 1990, 259:E312-E318.
Asada et al., “Inhibitory effects of prostacyclin analogue, TFC-132, on aortic neointimal thickening in vivo and smooth muscle cell proliferation in vitro,”Prostaglandins Leukot. Essen. Fatty Acids, 1994, 51:245-248.
Barrett et al., “Advances in Cytochemical Methods for Detection of Apoptosis,”J. Histochem. Cytochem, 2001, 49:821-832.
Benter et al., “Cardiovascular actions of angiotensin-(1-7),”Peptides, 1993, 14:679-684.
Benter et al., “Antihypertensive Actions of Angiotensin-(1-7) in Spontaneously Hypertensive Rats,”Am. J. Physiol. Heart Circ. Physiol, 1995, 269:H313-H319.
Britto et al., “Role of Angiotensin-(1-7) in the Modulation of the Baroreflex in Renovascular Hypertensive Rats,”Hypertension, 1997, 30:549-556.
Brosnihan et al., “Angiotensin-(1-7) Dilates Canine Coronary Arteries Through Kinins and Nitric Oxide,”Hypertension, 1996, 27:523-528.
Bumpus et al., “Nomenclature for Angiotensin Receptors. A Report of the Nomenclature Committee of the Council for High Blood Pressure Research,”Hypertension, 1991, 17:720-721.
Carey “Role of the Angiotensin AT2Receptor in Blood Pressure Regulation and Therapeutic Implications,”Am. J. Hypertens, 2001, 14:98S-102S.
Campbell et al., “Nephrectomy, Converting Enzyme Inhibition, and Angiotensin Peptides,”Hypertension, 1993, 22:513-522.
Chappell et al. , “Identification of angiotensin-(1-7) in rat brain: evidence for differential processing of angiotensin peptides,”J. Biol. Chem. 1989, 264:16518-16523.
Chappell et al., “Characterization of angiotensin II receptor subtypes in pancreatic acinar AR42J cells,”Peptides, 1995, 16:741-747.
Chappell et al., “Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme,”Hypertension, 1998, 31:362-367.
Chappell et al., “Processing of angiotensin peptides by NG108-15 neuroblastoma X glioma hybrid cell line,”Peptides, 1990, 11:375-380.
Chappell et at., “Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC.3.4.24.15) in vascular smooth muscle cells,”J Vasc Biol Med, 1994, 5:129-137.
Clark et al., “Angiotensin-(1-7) binds to Specific Receptors on Cardiac Fibroblasts to Initiate Antifibrotic and Antitrophic Effects,”Am J. Physiol. Heart Circ. Physiol., 2001, 37:1141-1146.
Clay et al., “Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells,”Carcinogenesis, 1999, 20:1905-1911.
Cook et al., “Inhibition by cAMP of Ras-Dependent Activation of Raf.,”Science, 1993, 262:1069-1072.
Darius et al., “Effects of ciprostene on restenosis rate during therapeutic transluminal coronary angioplasty,”Prostaglandins in the Cardiovascular System, 1992, 305-311.
De Gasparo et al., “Proposed update of angiotensin receptor nomenclature,”Hypertension, 1995, 25:924-927.
Dellipizzi et al., “Natriuretic action of angiotensin(1-7),”Br. J. Pharmacol, 1994, 111:1-3.
Dellipizzi et al., “Renal actions of Angiotensin-(1-7): Comparison with Angiotensin II,”The Pharmacologist, 1992, 34:196 (Abstract 326).
Dey et al., “Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor,”Biochem. Biophys. Res. Commun, 2000, 38-43.
Duhe et al., “Negative regulation of Janus kinases,”Cell Biochem. Biophys. 2001, 34:17-59.
Ellefson et al., “Synergistic effects of co-administration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice,”Cancer. Chemother. Pharmacol, 2004, 53:15-24.
Felix et al., “Neurophysiological responses to angiotensin-(1-7),”Hypertension, 1991, 17:1111-1114.
Fernandes, et al., “ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells,”Int.J.Cancer. 1999, 83:564-570.
Ferrario et al., “Counterregulatory actions of angiotensin-(1-7),”Hypertension, 1997, 30:535-541.
Fontes et al., “Evidence that angiotensin-(1-7) plays a role in the central control of blood pressure at the ventro-lateral medulla acting through specific receptors,”Brain Res. 1994, 665:175-180.
Freeman et al., “Angiotensin-(1-7) [Ang-(1-7)] inhibits vascular smooth muscle growth,”Hypertension. 1993, 41: 414.
Freeman et al., “Angiotensin-(1-7) Inhibits Vascular Smooth Muscle Cell Growth,”Hypertension, 1996, 28:104-108.
Gallagher et al., “Estrogen Regulation of Angiotensin-Converting Enzyme mRNA,”Hypertension, 1999, 33:323-328.
Gallagher et al., “Inhibition of Human Lung Cancer Cell Growth by Angiotensin-(1-7),”Carcinogenesis, 2004, 25(11):2045-2052.
Gallagher et al., “Molecular mechanisms for inhibition of human lung cancer cell growth by angiotensin,” Proceedings of American Cancer Research, 43:759, Abstract No. 3767 presented at 93rdAnnual Meeting Apr. 6-10, 2002, San Francisco.
Gao et al., “Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells,”FEBS Lett., 2001, 488:179-184.
Garcia et
Ferrario Carlos M.
Gallagher Patricia E.
Tallant E. Ann
Audet Maury
Kilpatrick Townsend & Stockton LLP
Wake Forest University Health Sciences
LandOfFree
Angiotensin-(1-7) and angiotensin-(1-7) agonists for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiotensin-(1-7) and angiotensin-(1-7) agonists for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiotensin-(1-7) and angiotensin-(1-7) agonists for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4254959